Screening for colorectal cancer in a community population
Colorectal Cancer Screening Cohort Study in Shougang Community Population Based on Polygene Methylation Detection Technology
This study is testing a new way to screen for colorectal cancer using genetic markers in people aged 40 and older to see if it helps catch the disease earlier.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 18000 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | Singlera Genomics Inc. Industry-sponsored |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05485077 on ClinicalTrials.gov |
What this trial studies
This study aims to validate the effectiveness of polygene methylation detection for colorectal cancer screening in a large community cohort. Participants aged 40 and older will complete a risk assessment questionnaire and undergo various tests, including fecal immunochemical tests and blood tests for cancer markers. Those with positive results will receive a colonoscopy for further examination and diagnosis. Follow-up assessments will occur at 1, 2, 3, 4, and 5 years to monitor outcomes and survival rates.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 40 and older who are capable of completing the required assessments and follow-ups.
Not a fit: Patients with a history of colorectal cancer or other malignancies, or those who have undergone colorectal resection, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve early detection and screening methods for colorectal cancer, potentially leading to better patient outcomes.
How similar studies have performed: Other studies have shown promise in using polygene methylation detection for cancer screening, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Chronological age ≥40 years; 2. Full capacity for action; 3. After enrollment, the participants were able to complete the Colorectal Cancer Risk Factor Assessment Questionnaire and the annual follow-up interviews; 4. In the course of the study, the information related to tumor diagnosis in other hospitals can be timely fed back to the researchers; Exclusion Criteria: 1. History of colorectal cancer and other malignant tumors; 2. Previous colorectal resection; 3. undergoing any cancer-related treatment; 4. Patients who have received major surgical treatment such as blood transfusion or transplantation within 3 months; 5. Participate in other interventional clinical investigators within 3 months; 6. Pregnant or lactating women; 7. Have autoimmune disease, hereditary disease, mental illness/disability, etc 8. Poor compliance, unable to complete the study.
Where this trial is running
Beijing, Beijing Municipality
- Peking University Shougang Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Rui Liu, Doctor — Singlera Genomics Inc.
- Study coordinator: Jin Gu, Doctor
- Email: yuanping_632@163.com
- Phone: 010-57830127
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.